Physician profile
Eric C Johnson
NPI 1902812803
$3,624.67
in general payments reported to CMS, 2019-2025
36 companies · $532 in 2025
The $532 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $23.90 · 2021: $319 · 2022: $122 · 2023: $744 · 2024: $978 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.80 | 2021-2025 | |
| Novo Nordisk INC | $423.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $349.33 | 2019-2025 | Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.63 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $266.67 | 2019-2025 | |
| Lilly USA, LLC | $205.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $159.49 | 2019-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $153.15 | 2019-2025 | Veozah |
| Corium, LLC | $110.80 | 2023-2024 | Azstarys |
| Amgen INC. | $100.52 | 2019-2023 | Repatha, Otezla |
| Daiichi Sankyo INC. | $72.74 | 2019-2024 | Injectafer |
| Exact Sciences Corporation | $68.37 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $53.04 | 2019 | |
| Phathom Pharmaceuticals, INC. | $51.43 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.40 | 2025 | Caplyta |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.